cyclo[Pro(4-OCO-NH-CH2-CH2-NH-Boc)-Phg-D-Trp(BoC)-Lys(Boc)-Tyr(Bzl)-Phe] | 842149-91-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: cyclo[Pro(4-OCO-NH-CH2-CH2-NH-Boc)-Phg-D-Trp(BoC)-Lys(Boc)-Tyr(Bzl)-Phe]
• 英文别名: Cyclo[(2S)-2-phenylglycyl-1-[(1,1-dimethylethoxy)carbonyl]-D-tryptophyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-O-(phenylmethyl)-L-tyrosyl-L-phenylalanyl-(4R)-4-[[[[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]carbonyl]oxy]-L-prolyl]；tert-butyl 3-[[(3S,6S,9S,12R,15S,18S,20R)-3-benzyl-9-[4-[(2-methylpropan-2-yl)oxycarbonylamino]butyl]-20-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylcarbamoyloxy]-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-12-yl]methyl]indole-1-carboxylate
• CAS: 842149-91-1
• 化学式: C₇₃H₉₀N₁₀O₁₅
• 分子量: 1347.58
• InChiKey: VVUKTNICRCMAJD-NUXYNHCKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.2
• 重原子数：
  98
• 可旋转键数：
  26
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  321
• 氢给体数：
  8
• 氢受体数：
  15

反应信息

• 作为反应物：
  描述：

  cyclo[Pro(4-OCO-NH-CH2-CH2-NH-Boc)-Phg-D-Trp(BoC)-Lys(Boc)-Tyr(Bzl)-Phe] 在 三异丙基硅烷 、 三氟乙酸 作用下， 以 水 为溶剂， 反应 1.0h， 生成 帕瑞肽
  参考文献：
  名称：

  [EN] NOVEL PROCESS FOR THE PREPARATION OF PASIREOTIDE
  [FR] NOUVEAU PROCÉDÉ DE PRÉPARATION DE PASIRÉOTIDE

  摘要：

  本发明涉及一种用于制备化学式11的帕西瑞肽的新型工艺。该发明还涉及一种化学式8的新型中间化合物及其制备工艺，该中间化合物用于制备化合物11。

  公开号：

  WO2016207912A1
• 作为产物：
  描述：

  H-Phe-(2S,4R)-(4-OCO-NH-CH2-CH2-NH-Boc)-Pro-Phg-D-Trp(Boc)-Lys(Boc)-Tyr(Bzl)-OH 在 二苯基磷酸 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 cyclo[Pro(4-OCO-NH-CH2-CH2-NH-Boc)-Phg-D-Trp(BoC)-Lys(Boc)-Tyr(Bzl)-Phe]
  参考文献：
  名称：

  A Novel Somatostatin Mimic with Broad Somatotropin Release Inhibitory Factor Receptor Binding and Superior Therapeutic Potential

  摘要：

  A rational drug design approach, capitalizing on structure-activity relationships and involving transposition of functional groups from somatotropin release inhibitory factor (SRIF) into a reduced size cyclohexapeptide template, has led to the discovery of SOM230 (25), a novel, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1-sst5). SOM230 has potent, long-lasting inhibitory effects on growth hormone and insulin-like growth factor-1 release and is a promising development candidate currently under evaluation in phase I clinical trials.

  DOI：

  10.1021/jm021093t

文献信息

• [EN] NOVEL PROCESS FOR THE PREPARATION OF PASIREOTIDE<br/>[FR] NOUVEAU PROCÉDÉ DE PRÉPARATION DE PASIRÉOTIDE
  申请人：BIOPHORE INDIA PHARMACEUTICALS PVT LTD

  公开号：WO2016207912A1

  公开（公告）日：2016-12-29

  The present invention relates to a novel process for the preparation of Pasireotide of formula 11 [Cyclo [Phe-4-(OCO-NH-CH2-CH2-NH2)) Pro}-Phg-DTrp-Lys-Tyr(Bzl)]]. The invention also relates to a novel intermediate compound of formula 8 and process thereof which is used for preparation of compound of formula 11.

  本发明涉及一种用于制备化学式11的帕西瑞肽的新型工艺。该发明还涉及一种化学式8的新型中间化合物及其制备工艺，该中间化合物用于制备化合物11。
• US7615609B2
  申请人：——

  公开号：US7615609B2

  公开（公告）日：2009-11-10
• A Novel Somatostatin Mimic with Broad Somatotropin Release Inhibitory Factor Receptor Binding and Superior Therapeutic Potential
  作者：Ian Lewis、Wilfried Bauer、Rainer Albert、Nagarajan Chandramouli、Janos Pless、Gisbert Weckbecker、Christian Bruns

  DOI：10.1021/jm021093t

  日期：2003.6.1

  A rational drug design approach, capitalizing on structure-activity relationships and involving transposition of functional groups from somatotropin release inhibitory factor (SRIF) into a reduced size cyclohexapeptide template, has led to the discovery of SOM230 (25), a novel, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1-sst5). SOM230 has potent, long-lasting inhibitory effects on growth hormone and insulin-like growth factor-1 release and is a promising development candidate currently under evaluation in phase I clinical trials.